Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Sidney Kimmel Cancer Center at Thomas Jefferson University

Status and phase: Withdrawn; Phase 1

Conditions: Plasma Cell Leukemia; Multiple Myeloma

Treatments: Drug: Bendamustine

Study type: Interventional

Funder types: Other

Identifiers

NCT02315157

14D.244

JT 5775 (Other Identifier)

2014-009 (Other Identifier)

Details and patient eligibility

About

This phase I trial studies the side effects and best dose of bendamustine hydrochloride in treating patients with previously treated multiple myeloma. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Full description

PRIMARY OBJECTIVES:

I. To identify a maximum tolerated dose of bendamustine (bendamustine hydrochloride) in patients with multiple myeloma.

SECONDARY OBJECTIVES:

I. To evaluate the safety of escalating doses of bendamustine in patients with multiple myeloma.

II. To describe the response after bendamustine

OUTLINE: This is a dose-escalation study.

Patients receive bendamustine hydrochloride intravenously (IV) over 60-180 minutes on days 1 and 2.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with multiple myeloma who have not achieved a CR following at least 4 cycles of induction therapy
2. Age up to 80 years
3. ECOG Performance Status of 0 or 1
4. Left ventricular ejection fraction =/> 40%. No uncontrolled arrhythmias or symptomatic cardiac disease
5. FEV1, FVC and DLCO =/> 40%. No symptomatic pulmonary disease.
6. Serum bilirubin <2 x upper limit of normal, alkaline phosphatase <3 x upper limit of normal. No evidence of chronic active hepatitis or cirrhosis. No effusion or ascites > 1 L prior to drainage.
7. HIV negative
8. Negative beta HCG test in woman with child bearing potential, defined as not post-menopausal for 12 months or no previous sterilization
9. Patients or guardian able to sign informed consent
10. Availability of previously collected autologous stem cells (at least 3.0 x 106 CD34 cells/kg)
11. Calculated GFR > 50 ml/minute

Exclusion criteria

1. Patients with uncontrolled hypertension (systolic > 140, diastolic > 90 despite antihypertensive therapy
2. Patients with uncontrolled bacteria, viral or fungal infections (currently taking medication and progression of clinical symptoms)
3. New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
4. Relapsed/refractory myeloma

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

Bendamustine 200 mg/m2

Experimental group

Description:

Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).

Treatment:

Drug: Bendamustine

Bendamustine 250 mg/m2

Experimental group

Description:

Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).

Treatment:

Drug: Bendamustine